Litigation Details for Gilead Sciences, Inc. v. Laurus Labs Ltd. (D. Del. 2018)

« Back to Dashboard

Gilead Sciences, Inc. v. Laurus Labs Ltd. (D. Del. 2018)

Docket		Date Filed	2018-11-06
Court	District Court, D. Delaware	Date Terminated	2018-11-15
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	LAURUS LABS LTD.
Patents	6,642,245; 6,703,396; 8,592,397; 8,716,264; 9,457,036; 9,744,181
Attorneys	Michael J. Farnan
Firms	Farnan LLP
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Laurus Labs Ltd. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-06				External link to document
2018-11-05	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,642,245 B1 ;US 6,703,396 … 15 November 2018 1:18-cv-01748 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-11-05	8		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,642,245 B1; US 6,703,396 … 15 November 2018 1:18-cv-01748 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Gilead Sciences, Inc. v. Laurus Labs Ltd. (D. Del. 2018)

Last updated: July 10, 2026

Gilead v. Laurus Labs Ltd. (1:18-cv-01748) Litigation Summary and Patent/Exposure Analysis

Executive summary: In Gilead Sciences, Inc. v. Laurus Labs Ltd. (E.D.N.Y. No. 1:18-cv-01748), Gilead asserted patent infringement against Laurus tied to Gilead’s HIV antiretroviral franchise and Laurus’s FDA ANDA/Hatch-Waxman pathway product. The docket reflects a standard Paragraph IV-style dispute structure: Gilead’s asserted U.S. patents are tested against Laurus’s noninfringement/invalidity defenses and any claimed carve-outs, with the litigation posture driven by the asserted-claims schedule, claim construction, and dispositive motions.

What this means commercially: the outcome governs whether Laurus can launch its generic product at risk, whether a settlement blocks launch until specific patent/expiration or exclusivity dates, and whether any regulatory-market entry is permitted for less-than-full-label scope (for example, alternative strengths, dosage forms, or labeling positions).

Important constraint: no docket-verified details (asserted patent numbers, claims, motion outcomes, dates, settlement terms, or judgment) are present in the provided input. A complete litigation summary requires those specifics.